April 9, 2013
Although the outlook for patients with multiple myeloma, a cancer that attacks blood plasma and bone marrow, is typically dismal, F-18 FDG PET/CT has emerged as a strategy that could provide earlier diagnosis as well as more accurate treatment monitoring and patient prognosis, according to a review in the April issue of the American Journal of Roentgenology .
An estimated 20,000 new diagnoses of multiple myeloma are made in the U.S. annually. About half that number of people are expected to die of the disease every year. Multiple myeloma is ranked the number one cause of primary bone cancers and second in incidence of blood malignancy. The workhorse of myeloma imaging has been radiography for some time, but F-18 FDG PET/CT may offer a potential alternative to radiography, according to Ankit Agarwal, MD, from the department of radiology at Boston University School of Medicine, and colleagues